3-methyl-4-({3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyloxy)methyl]oxan-2-yl}oxy)octanoic acid



Compound IDCDAMM00204
Common name3-methyl-4-({3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyloxy)methyl]oxan-2-yl}oxy)octanoic acid
IUPAC name3-methyl-4-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxan-2-yl]oxyoctanoic acid
Molecular formulaC22H32O12

Experimental data

Retention time47.23
Adduct[M+NH4]+
Actual mz506.224
Theoretical mz506.223
Error1.2
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0823

Identifiers and class information

Inchi keyPCVSDYZWDASYAF-WOBSCQHONA-N
SmilesCCCCC(C(C)CC(=O)O)OC1C(C(C(C(O1)COC(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O
SuperclassLipids and lipid-like molecules
ClassFatty Acyls

Pharmacokinetic properties

Number of descriptor values(#stars)5
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)17
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)488.488
Computed dipole moment(dipole)5.27
Total solvent accessible surface area (SASA)794.758
Hydrophobic component of SASA (FOSA)339.608
Hydrophilic component of SASA (FISA)377.099
Pie component of the SASA (PISA)78.051
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1465.51
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)14.75
Free energy of solvation of dipole (dip^2/V)0.0189501
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0491028
Globularity descriptor (glob)0.785096
Predicted polarizability in cubic angstroms (QPpolrz)42.325
Predicted hexadecane/gas partition coefficient (QPlogPC16)16.737
Predicted octanol/gas partition coefficient (QPlogPoct)32.853
Predicted water/gas partition coefficient (QPlogPw)25.758
Predicted octanol/water partition coefficient (QPlogPo/w)-0.251
Predicted aqueous solubility (QPlogS)-2.884
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.518
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.574
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.666
Predicted brain/blood partition coefficient (QPlogBB)-4.54
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.232
Predicted skin permeability, log Kp (QPlogKp)-6.562
PM3 calculated ionization potential (IP(ev))9.258
PM3 calculated electron affinity (EA(eV))0.492
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)-1.12
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)224.339
Number of nitrogen and oxygen atoms (#NandO)12
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P05121SERPINE1Plasminogen activator inhibitor-1T15556SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P14679TYRTyrosinaseT97035SEA
P20916MAGMyelin-associated glycoprotein (by homology)T95286SEA
P04637TP53Tumour suppressor p53/oncoprotein Mdm2T15739SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T15556DI0037Asthma[ICD-11: CA23]P05121SERPINE1
T15556DI0405Thrombosis[ICD-11: DB61-GB90]P05121SERPINE1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T95286DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P20916MAG
T15739DI0233Lip/oral cavity/pharynx neoplasm[ICD-11: 2B6E]P04637TP53
T15739DI0323Ovarian dysfunction[ICD-11: 5A80]P04637TP53
T15739DI0413Transplant rejection[ICD-11: NE84]P04637TP53
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP

Copyright © 2025